OBJECTIVES Arachidonic acid (AA), an omega-6 (n-6) fatty acid, can be converted to inflammatory leukotrienes (LTs) by 5-lipoxygenase (5-LO), which is activated by 5-lipoxygenase-activing protein (FLAP) and then lead to the expression of LTB4, which play a role in coronary heart disease (CHD).omega-3 (n-3) fatty acids are the metabolic counterparts to n-6 fatty acids and have anti-inflammatory effects. Thus, the tissue ratio of n-6/n-3 fatty acids may influence LT production. However, whether alteration of tissue n-6/n-3 fatty acid ratio has an effect on 5-LO and FLAP expression is not well known. The fat-1 transgenic mouse, expressing an n-3 fatty acid desaturase, is capable of endogenously converting n-6 fatty acids to n-3 fatty acids, and thereby has a tissue n-6/n-3 fatty acid ratio close to 1:1. The aim of the study was to compare 5-LO and FLAP expression status in immune cells between fat-1 transgenic mice and wild type (WT) littermates.
METHODS
Immune cells from fat-1 transgenic mice (n¼5) and WT mice (n¼5) were harvested from the spleen and cultured for 24h. Mononuclear cells were also isolated from the blood. Cellular n-6/n-3 fatty acid profiles were analyzed using gas chromatography. The mRNA and protein expressions of 5-LO and FLAP in the cells were evaluated using real time RT-PCR and immunoblot (WB) assays, respectively. the expression of LTB4 level was assessed by Elisa assay.
RESULTS He fat-1 transgenic mice showed a lower ratio of n-6/n-3 fatty acids than WT mice in both splenocytes and blood monocytes (AA: 4.53AE0.10 VS 2.16AE0.09; EPA: 0.13AE0.07 VS 0.36AE0.15; DHA: 0.49AE0.14 VS 2.17AE0.76; Total u-3: 0.68AE0.29 VS 2.66AE0.70; u-6/u-3:
9.49AE4.70 VS 1.32AE0.36). The mRNA expressions of 5-LO and FLAP were significantly lower in the cells of fat-1 mice than in those of WT mice. Accordingly, the protein levels of 5-LO and FLAP were also markedly lower in fat-1 mice than in WT mice. The LTB4 level was also lower in fat-1 mice than WT mice.
CONCLUSIONS Our findings demonstrate that a decreased tissue n-6/ n-3 fatty acid ratio reduces 5-LO and FLAP expression. This study suggests a role for tissue n-6/n-3 fatty acid ratio in the 5-LO pathway of AA metabolism in immune cells, and a new mechanism for the antiinflammatory effect of n-3 fatty acids, omega-3 fatty acid may play a role in the prevention of CHD. METHODS Male Sprague-Dawley rats were subjected to shamoperation or MI by ligating the left anterior descending coronary artery. The rats with MI were treated with vehicle, PJS at the dose of 3 g/kg/day and 6 g/kg/day, or losartan at the dose of 10 mg/kg/day 24h after MI. The rats in the vehicle group and the sham-operation group were intragastrically given at the same dosage of normal saline. One weeks later, we determined the effects of PJS and losartan on cardiac function, and the distribution and level of collagen using echocardiography, Masson's trichrome stain and hydroxyproline assay, respectively. The myocardial expression of TGF-b/Smads signaling pathway was determined by the use of Western blot. [This work was supported by a grant from the National Natural Science Foundation of China (No. 81173410)].
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Fufangxueshuantong ameliorates diabetic cardiomyopathy in rats by attenuating cardic and metabolic dysfunction Jing Han, Yan Wu, Tiantian Lv, Hongliang Wang, Gaimei Hao, Jie He, Wei Wang Beijing University of Chinese Medicine OBJECTIVES Diabetic cardiomyopathy (DCM) can cause diastolic and systolic dysfunction damage, resulting in myocardial ischemia and heart failure. Fufangxueshuantong (FXST), which is composed of Panax notoginseng, Salvia miltiorrhiza, Astragalus membranaceus and Scrophularia ningpoensis, has been used for the treatment of angina pectoris and diabetic retinopathy for years. However, whether FXST has an effect on DCM is unknown. Metabolic dysfunction occurs in hearts and contributes to DCM. Adenosine monophosphate-activated protein kinase (AMPK), peroxisome proliferator activated receptorg coactivator 1 (PGC1a) and silent information regulator 1(sirt1) signaling pathways sense the metabolic demands and impinge on expression of genes encoding for metabolic enzymes (citrate synthase(CS), etc). So the present study aims to demonstrate that whether FXST treatment can ameliorate cardiac function in diabetic rats and to illustrate its effect on energy metabolic mechanism.
METHODS SD rats were randomly divided into 3 groups: normal group, diabetic group, diabeticþFXST group. 20 weeks after streptozocin induction, FXST or water was administered for 16 weeks. Cardiac dimensions and function were determined by echocardiography. Left ventricular internal diameter during diastole (LVIDd) and systole (LVIDs) were assessed in M-mode, and ejection fraction (EF), fractional shortening (FS) and left ventricular mass (LV mass) were calculated with the M-mode measurements. Doppler echocardiography was used to measure IVRT (Isovolumic relaxation time) and E/A (Ratio of peak early to late transmitral blood flow velocities). After echocardiographic detection, the indicators of energy metabolism (CS, AMPK, PGC1a, sirt1) in hearts were detected through PCR.
RESULTS Echocardiography revealed that in the diabetic group, a decrease in E/A and an increase in IVRT were observed in the rats (vs. normal group). Following treatment with FXST in the diabetic rats, E/A was found to be upregulated, (vs. diabetic group). In the diabetic group, a decrease in EF, FS, LV mass and an increase in LVIDd, LVIDs were observed in the rats (vs. normal group). Following treatment with FXST in the diabetic rats, EF and FS were found to be upregulated, while LVIDd and LVIDs were markedly decreased (vs. diabetic group).
Real time PCR analysis revealed decreased content of PGC1a, sirt1 and increased levels of CS, AMPK in the diabetic group when compared with the normal group. However, increased levels of (CS, AMPK, PGC1a, sirt1) were observed in the FXST-treated group when compared with the diabetic group.
CONCLUSIONS Our study demonstrated that diabetes induced diabetic cardiomyopathy, characterized by both diastolic and systolic dysfunction and metabolic dysfunction in heart. And FXST protected DCM via attenuating cardiac function. In addition, therapeutic FXST administration can promote gene levels of energy metabolism. These findings provide evidence as to the cardiac protective efficacy of FXST to DCM.
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Cardioprotective effect of propofol against oxygen glucose deprivation and reperfusion injury in H9c2 cells OBJECTIVES The intravenous anesthetic propofol is reported to be a cardioprotective agent against ischemic-reperfusion injury in the heart. However, the regulatory mechanism still remains unclear.
METHODS In the study, we used H9c2 cell line under condition of oxygen glucose deprivation (OGD) followed by reperfusion (OGD/R) to 
